Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormon-Releasing-Hormon (LHRH) Agonists.
Advanced Prostate Cancer
Conditions: official terms
Prostatic Neoplasms
Study Type
Study Phase
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Name: Degarelix Type: Drug
Name: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat) Type: Drug
Overall Status
The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Male
Criteria: Inclusion Criteria:

- Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC)

- Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment

Exclusion Criteria:

- Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline.

- Participation in a clinical trial at baseline and during the follow-up period
Investigational site (there may be other sites in this country)
Rottweil, Germany
Status: Recruiting
Start Date
September 2014
Completion Date
December 2018
Ferring Pharmaceuticals
Ferring Pharmaceuticals
Record processing date processed this data on July 28, 2015 page